Author(s): Zaman K, Sack DA, Yunus M, Arifeen SE, Podder G,
Abstract Share this page
Abstract Co-administration of oral live-attenuated human rotavirus vaccine RIX4414 (Rotarix) and oral polio vaccine (OPV) was assessed. Healthy infants were randomised to receive 2-doses of either: RIX4414 or placebo co-administered with OPV (12 and 16 weeks of age); or RIX4414 or placebo given 15 days after OPV. After vaccination, 56.5-66.7\% of RIX4414 and 18.6\% of placebo recipients had seroconverted for rotavirus IgA. No significant differences between RIX4414 groups with or without OPV co-administration were observed. No statistically significant differences were observed between groups for polio seroprotection rates. RIX4414 vaccine was immunogenic when co-administered with OPV and did not interfere with OPV seroprotection rates. TRIAL REGISTRATION: ClinicalTrials.gov NCT00139334.
This article was published in Vaccine
and referenced in Journal of Vaccines & Vaccination